BRPI0409976A - composto, métodos para retardar a progressão de igt diabetes do tipo 2, para retardar a progressão de diabetes do tipo 2 para diabetes que requer insulina, para tratar obesidade ou prevenir excesso de peso para regular o apetite para induzir saciedade, para prevenir ganho de peso após se ter tido sucesso em perder peso, para aumentar dispêndio de energia, para tratar uma doença ou estado e para tratar bulimia, composição farmacêutica, e, uso de um composto - Google Patents

composto, métodos para retardar a progressão de igt diabetes do tipo 2, para retardar a progressão de diabetes do tipo 2 para diabetes que requer insulina, para tratar obesidade ou prevenir excesso de peso para regular o apetite para induzir saciedade, para prevenir ganho de peso após se ter tido sucesso em perder peso, para aumentar dispêndio de energia, para tratar uma doença ou estado e para tratar bulimia, composição farmacêutica, e, uso de um composto

Info

Publication number
BRPI0409976A
BRPI0409976A BRPI0409976-1A BRPI0409976A BRPI0409976A BR PI0409976 A BRPI0409976 A BR PI0409976A BR PI0409976 A BRPI0409976 A BR PI0409976A BR PI0409976 A BRPI0409976 A BR PI0409976A
Authority
BR
Brazil
Prior art keywords
diabetes
treat
compound
progression
type
Prior art date
Application number
BRPI0409976-1A
Other languages
English (en)
Inventor
Ulrich Sensfuss
Kilian Waldemar Conde Frieboes
Leif Christensen
Ingrid Vivika Petterson
Thomas Kruse Hansen
Michael Ankersen
Kjeld Madsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BRPI0409976A publication Critical patent/BRPI0409976A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)

Abstract

"COMPOSTO, MéTODOS PARA RETARDAR A PROGRESSãO DE IGT PARA DIABETES DO TIPO 2, PARA RETARDAR A PROGRESSãO DE DIABETES DO TIPO 2 PARA DIABETES QUE REQUER INSULINA, PARA TRATAR OBESIDADE OU PREVENIR EXCESSO DE PESO, PARA REGULAR O APETITE, PARA INDUZIR SACIEDADE, PARA PREVENIR GANHO DE PESO APóS SE TER TIDO SUCESSO EM PERDER PESO, PARA AUMENTAR DISPêNDIO DE ENERGIA, PARA TRATAR UMA DOENçA OU ESTADO E PARA TRATAR BULIMIA, COMPOSIçãO FARMACêUTICA, E, USO DE UM COMPOSTO". Peptídeos lineares e cíclicos inéditos da fórmula R¬ 1¬ -x-x¬ 1¬-x¬ 2¬-X¬ 3¬-x¬ 4¬-X¬ 5¬-X¬ 6¬-X¬ 7¬-X¬ 8¬-X¬ 9¬-X¬ 10¬-X¬ X¬ 11¬-R¬ 2¬ são úteis no tratamento de obesidade.
BRPI0409976-1A 2003-05-09 2004-05-05 composto, métodos para retardar a progressão de igt diabetes do tipo 2, para retardar a progressão de diabetes do tipo 2 para diabetes que requer insulina, para tratar obesidade ou prevenir excesso de peso para regular o apetite para induzir saciedade, para prevenir ganho de peso após se ter tido sucesso em perder peso, para aumentar dispêndio de energia, para tratar uma doença ou estado e para tratar bulimia, composição farmacêutica, e, uso de um composto BRPI0409976A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200300706 2003-05-09
US47063903P 2003-05-15 2003-05-15
DKPA200400172 2004-02-05
US54396204P 2004-02-12 2004-02-12
PCT/DK2004/000308 WO2004099246A2 (en) 2003-05-09 2004-05-05 Peptides for use in treating obesity

Publications (1)

Publication Number Publication Date
BRPI0409976A true BRPI0409976A (pt) 2006-05-09

Family

ID=38605530

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409976-1A BRPI0409976A (pt) 2003-05-09 2004-05-05 composto, métodos para retardar a progressão de igt diabetes do tipo 2, para retardar a progressão de diabetes do tipo 2 para diabetes que requer insulina, para tratar obesidade ou prevenir excesso de peso para regular o apetite para induzir saciedade, para prevenir ganho de peso após se ter tido sucesso em perder peso, para aumentar dispêndio de energia, para tratar uma doença ou estado e para tratar bulimia, composição farmacêutica, e, uso de um composto

Country Status (7)

Country Link
US (1) US20090088388A1 (pt)
EP (1) EP1625158A2 (pt)
JP (1) JP2007524584A (pt)
AU (1) AU2004235872A1 (pt)
BR (1) BRPI0409976A (pt)
CA (1) CA2523408A1 (pt)
WO (1) WO2004099246A2 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1667724A2 (en) * 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
EP1670815A2 (en) 2003-09-30 2006-06-21 Novo Nordisk A/S Melanocortin receptor agonists
JP2008519006A (ja) * 2004-11-04 2008-06-05 ノボ ノルディスク アクティーゼルスカブ 肥満症の治療に使用するためのペプチド
US20110098213A1 (en) * 2004-11-04 2011-04-28 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
CN101052649A (zh) * 2004-11-04 2007-10-10 诺和诺德公司 用于治疗肥胖的肽类
CN101052650A (zh) * 2004-11-04 2007-10-10 诺和诺德公司 用于治疗肥胖的新颖的肽类
WO2006073771A2 (en) * 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
WO2006097526A1 (en) * 2005-03-17 2006-09-21 Novo Nordisk A/S Compounds for use in the treatment of obesity
US8603972B2 (en) 2005-03-18 2013-12-10 Novo Nordisk A/S Extended GLP-1 compounds
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
EP1874813A2 (en) * 2005-04-14 2008-01-09 Novo Nordisk A/S Trimeric peptides for use in treating obesity
CN101222942A (zh) * 2005-07-18 2008-07-16 诺沃-诺迪斯克有限公司 用于治疗肥胖的肽
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
EP2001875A2 (en) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
EP2049518B1 (en) 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
EP2106407A2 (en) * 2007-01-18 2009-10-07 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
US20100022446A1 (en) * 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
WO2008087186A2 (en) * 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
US20100016238A1 (en) * 2007-01-18 2010-01-21 Novo Nordisk A/S Peptides for Use in the Treatment of Obesity
US20100056433A1 (en) * 2007-01-18 2010-03-04 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
BRPI0819188B1 (pt) 2007-11-05 2021-06-22 Ipsen Pharma S.A.S. Uso de melanocortinas para a preparação de um medicamento para tratar resistência à insulina
EP2283037A1 (en) * 2008-05-22 2011-02-16 Novo Nordisk A/S Process
WO2009151383A1 (en) * 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for the treatment of obesity and other diseases associated with melanocortin receptor function
KR101687037B1 (ko) 2008-06-09 2016-12-15 팔라틴 테크놀로지스 인코포레이티드 성기능 장애 치료용 멜라노코르틴 수용체-특이적 펩티드
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
JP4864064B2 (ja) 2008-10-30 2012-01-25 エムジーファーマ株式会社 抗糖尿病作用を有するペプチドおよびその用途
MX2011007736A (es) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Compuestos de hormona del crecimiento estables.
CA2761607C (en) 2009-06-08 2018-09-04 Yi-Qun Shi Melanocortin receptor-specific peptides
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es) * 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
BR112012011780A2 (pt) 2009-11-23 2019-09-24 Palatin Technologies, Inc peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano
JP5999702B2 (ja) 2009-11-23 2016-09-28 パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. メラノコルチン−１受容体特異的環状ペプチド
RS59459B1 (sr) 2010-01-22 2019-11-29 Novo Nordisk Healthcare Ag Hormoni rasta sa produženom in-vivo efikasnošću
MX338357B (es) 2010-01-22 2016-04-13 Novo Nordisk Healthcare Ag Compuestos estables de la hormona de crecimiento.
DK2558105T3 (da) 2010-04-12 2020-01-27 Reata Pharmaceuticals Inc Bardoxolonmethyl til behandling af fedme
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
WO2015067715A2 (en) * 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
KR102620911B1 (ko) 2014-10-29 2024-01-05 질랜드 파마 에이/에스 Gip 효능제 화합물 및 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457864A (en) * 1981-10-23 1984-07-03 University Patents, Inc. Synthetic analogues of α-melanotropin
US5049547A (en) * 1988-02-11 1991-09-17 University Patents, Inc. Composition for stimulating integumental melanocytes
US5128448A (en) * 1990-01-10 1992-07-07 Hoffman-La Roche Inc. CCK analogs with appetite regulating activity
ES2146649T3 (es) * 1993-05-05 2000-08-16 Keith Rose Compuestos de polioximas y su preparacion.
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US6054556A (en) * 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
SI1315750T1 (sl) * 2000-08-30 2007-06-30 Hoffmann La Roche Cikliäśni peptidi kot agonisti za receptorje melanokortina-4
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity

Also Published As

Publication number Publication date
US20090088388A1 (en) 2009-04-02
CA2523408A1 (en) 2004-11-18
WO2004099246A2 (en) 2004-11-18
JP2007524584A (ja) 2007-08-30
WO2004099246A3 (en) 2005-05-19
AU2004235872A1 (en) 2004-11-18
EP1625158A2 (en) 2006-02-15

Similar Documents

Publication Publication Date Title
BRPI0409976A (pt) composto, métodos para retardar a progressão de igt diabetes do tipo 2, para retardar a progressão de diabetes do tipo 2 para diabetes que requer insulina, para tratar obesidade ou prevenir excesso de peso para regular o apetite para induzir saciedade, para prevenir ganho de peso após se ter tido sucesso em perder peso, para aumentar dispêndio de energia, para tratar uma doença ou estado e para tratar bulimia, composição farmacêutica, e, uso de um composto
BRPI0414890A (pt) composto, métodos de retardar a progressão de igt para diabete tipo 2, e de diabete tipo 2 para diabete que requer insulina, de tratar a obesidade ou prevenir o excesso de peso, de regular o apetite, de induzir saciedade, de impedir o ganho de peso, de aumentar o gasto de energia, e de tratar uma doença ou estado, composição farmacêutica, e, uso de um composto
NO20070585L (no) Humane anti-KIR antistoff.
AR046819A1 (es) Compuestos de piridina inhibidores de dipeptidil peptidasa
BRPI0508098A (pt) compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
EA200900626A1 (ru) Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и содержащими их фармацевтическими композициями
BRPI0510273A (pt) derivados de tetraazabenzo[e]azuleno e análogos destes
BRPI0512193A (pt) entidade quìmica, composição farmacêutica, métodos de tratamento de doença cardìaca, para modular o sarcÈmero cardìaco, e para potencializar miosina cardìaca em um mamìfero, uso de uma entidade quìmica, e, método de preparação de um composto
PL410218A1 (pl) Sposób wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycja otrzymana tym sposobem oraz jej zastosowanie
GB0504857D0 (en) Novel compounds and their effects on feeding behaviour
WO2006066244A3 (en) Method for extending lifespan and delaying the onset of age-related disease
AR069903A1 (es) Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer
BRPI0515328A (pt) composições hidráulicas flexìveis
BRPI0510453A (pt) composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
BRPI0507526A (pt) revestimento de dente, e, composição de revestimento de dente
BR0317872A (pt) Medicamentos antiinflamatórios
BRPI0508390B8 (pt) uso de um anticorpo antagonista anti-ngf, bem como kit e composição farmacêutica para tratamento de dor de câncer de osso
BR0313555A (pt) Aplicação de inibidores de ikb-cinase na terapia da dor
BR0214457A (pt) métodos para o tratamento de cáncer
BRPI0414185A (pt) método de controle da cura de uma pasta de cimentação de poço, e agente retardador para utilização em pasta para cimentação de poços
BRPI0514295A (pt) 1, 5-difenilpirazóis
BRPI0511703A (pt) composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o inìcio do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, sìndrome x, um distúrbio lipìdico, aterosclerose, e uma condição
BRPI0512974A (pt) novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas
BRPI0907502A2 (pt) pelo menos um entidade química, composição, e, métodos para tratar um paciente tendo uma condição, para aumentar a função ou atividade do músculo esquelético, para aumentar a eficiência do músculo esquelético, parab aumentar o tempo da fadiga de fibra muscular esquelética rápida, para sensibilizar uma fibra muscular esquelética rápida para produzir força em resposta a baixas concentreações de íons cálcio e para aumentar o tempo de fadiga muscular esquelética

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.